Liver neoplasms




Primary tumors of the liver are divided into epithelial and mesenchymal lesions and further classified as benign or malignant ( Table 20-1 ). Overall, metastatic tumors are more common than primary hepatic neoplasms. Clinical history, such as age of the patient and the involvement of the non-neoplastic liver by disease processes such as cirrhosis, can be helpful in the evaluation of hepatic masses.



TABLE 20-1

World Health Organization Classification of Primary Liver Mass Lesions










Epithelial Mass Lesions Nonepithelial Mass Lesions
Benign
Large regenerative nodule (macroregenerative nodule)
Low-grade dysplastic nodule
High-grade dysplastic nodule
Hepatic adenoma
Focal nodular hyperplasia
Bile duct adenoma
Bile duct hamartoma
Biliary cystadenoma
Intraductal biliary papillomatosis
Congenital biliary cyst
Focal fatty change
Malignant
Hepatocellular carcinoma
Hepatoblastoma
Cholangiocarcinoma
Biliary cystadenocarcinoma
Intraductal papillary adenocarcinoma
Benign
Hemangioma
Angiomyolipoma
Infantile hemangioendothelioma
Mesenchymal hamartoma
Localized fibrous tumor
Solitary necrotic nodule
Inflammatory pseudotumor
Malignant
Epithelioid hemangioendothelioma
Angiosarcoma
Undifferentiated (embryonal) sarcoma
Lymphoma
Kaposi’s sarcoma
Other rare sarcomas



Epithelial tumors


Hepatocellular tumors


Focal nodular hyperplasia


Focal nodular hyperplasia (FNH) is a localized hyperplastic overgrowth of hepatocytes around a vascular anomaly, particularly an arterial malformation, and may coexist with hepatic cavernous hemangiomas in about 20% of cases. Patients with multiple FNHs who have one or more other lesions, including hepatic hemangioma, berry aneurysms, and brain tumors (astrocytoma and meningioma), are considered to have the multiple FNH syndrome. Although FNH is generally considered non-neoplastic, some lesions appear to be monoclonal.


Clinical features


FNH is found mainly in women of reproductive age (80% to 95%). Oral contraceptive use is implicated in promotion of FNH growth but is generally not considered a causative factor. Up to 15% of cases occur in children and may be associated with glycogen storage disease type Ia. FNH is usually an incidental finding; nonspecific abdominal pain is the most common complaint in symptomatic patients. FNH may increase in size over time. The serum α-fetoprotein (AFP) level is normal.




FOCAL NODULAR HYPERPLASIA—FACT SHEET


Definition





  • Non-neoplastic mass lesion caused by nodular overgrowth of hepatocytes in region of altered hepatic blood flow



Incidence and location





  • Up to 0.6% in autopsy series



  • 2% of hepatic tumors in children



  • No geographic predilection



Morbidity and mortality





  • Low morbidity



  • Rupture is rare



  • No increase in mortality



Gender, race, and age distribution





  • More common in women than men, 9:1



  • Occurs in all age groups



  • No race predilection



Clinical features





  • Usually incidental finding



  • Associated with oral contraceptive use in 50% to 60% of cases



  • Rarely associated with abdominal pain, hepatomegaly, or tenderness



  • Associated with extrahepatic vascular lesions



Radiologic features





  • Central scar by ultrasonography, CT, MRI



  • Doppler imaging may detect feeding artery



  • Hypodense lesion on CT with enhancement during arterial phase



Prognosis and therapy





  • Prognosis is excellent; most patients remain asymptomatic



  • Treatment for asymptomatic lesions: observation



  • Surgical resection for symptomatic or enlarging lesions




Radiologic features


FNH is suggested when computed tomography (CT) or magnetic resonance imaging (MRI) shows a mass with a central scar, when angiography or Doppler ultrasonography discloses centrifugal hypervascularity, or when technetium 99 sulfur colloid scan shows normal or increased uptake. Sensitivity is around 70% for a preoperative diagnosis of FNH, and false-positive results are rare.


Pathologic features


Gross findings


FNH is usually a subcapsular, well-circumscribed, bulging, tan, nodular mass. Most measure less than 5 cm in diameter, but larger lesions occur. The surrounding liver is normal. The most characteristic finding is the presence of a central stellate scar with radiating fibrous septa that subdivide the mass into multiple smaller nodules ( Fig. 20-1 ). The central scar may be inconspicuous in smaller lesions. Hemorrhage, necrosis, and bile staining are rare.




FIGURE 20-1


Focal nodular hyperplasia (FNH) is a sharply circumscribed nodular mass often appearing lighter than the surrounding liver. The central stellate scar is characteristic.


Microscopic findings


FNH is composed of nodules of hepatocytes surrounded by fibrous septa that contain artery branches, bile ductules (a variable but key feature), a variable chronic and/or acute inflammatory infiltrate, and decreased or absent interlobular bile ducts and portal vein branches. The central scar is composed of dense collagen ( Fig. 20-2 A) and contains numerous thick-walled arteries and bile ductules (see Fig. 20-2 B). In the telangiectatic variant, numerous small, dilated vessels (resembling hemangioma) are seen centrally, and the adjacent sinusoids are markedly dilated. The histologic features overall resemble a biliary type of cirrhosis with ductopenia.




FIGURE 20-2


Focal nodular hyperplasia. A, The central stellate scar is composed of dense collagen. B, A variable degree of bile ductular proliferation is present at the interface of the scar with the parenchyma.


The hepatocytes in FNH lesions are similar to those in the surrounding liver, although they may be somewhat larger and paler and may incorporate variable quantities of fat or glycogen. Nuclear pleomorphism, prominent nucleoli, and mitotic figures are not found in classic FNH, but cytologic atypia may be seen in variant forms. The variant formerly referred to as “telangiectatic FNH” has been shown to be a form of hepatic adenoma by genetic and molecular studies.




FOCAL NODULAR HYPERPLASIA—PATHOLOGIC FEATURES


Gross findings





  • Single subcapsular lesion in right lobe



  • Average size less than 5 cm to 10 cm



  • Central stellate scar with radiating septa



Microscopic findings





  • Nodular overgrowth of normal-appearing hepatocytes



  • Large caliber vessels in central stellate scar



  • Bile ductular proliferation in scar



Fine-needle aspiration biopsy findings





  • Normal hepatocytes



  • Large flat sheets of hepatocytes have irregular edges



  • Fibrous tissue and bile duct epithelium helpful if present



Genetics





  • Clonality is reported in some cases



Differential diagnosis





  • Cirrhosis



  • HA




Ancillary studies


Fine-needle aspiration biopsy


Fine-needle aspiration (FNA) biopsies are generally not useful for definitive diagnosis because the central stellate scar is usually not represented. The hepatocytes of FNH are cytologically indistinguishable from normal.


Differential diagnosis


FNH may be confused on biopsy with cirrhosis, hepatic adenoma (HA) (especially the telangectatic variant), and well-differentiated hepatocellular carcinoma (HCC). The presence of biliary epithelium distinguishes FNH from HA. The localized nature of the lesion and its origin in normal liver exclude cirrhosis. Well-differentiated HCC generally displays more pronounced cellular atypia and may demonstrate vascular invasion. Glipican-3 immunohistochemistry (which may be used in combination with CD-34) can be useful in this setting, being positive in at least half of well-differentiated HCCs and negative in benign hepatocytic lesions.


Prognosis and therapy


Most FNHs are not progressive lesions, and they do not undergo malignant degeneration. Unlike hepatic adenomas, FNHs rarely rupture or cause intraperitoneal bleeding. Due to the low risk for complications and negligible risk for malignant transformation associated with these lesions, surgery may not be indicated. However, if imaging studies are not considered diagnostic, or if the patient has persistent symptoms, surgical management may be necessary.


Hepatic adenoma


Clinical features


HA is a benign hepatocellular neoplasm arising in a normal liver. The overwhelming majority of cases (95%) develop in women in their childbearing years, and long-term oral contraceptive steroid (OCS) use is a common risk factor. In men, HA is seen in the context of the use of anabolic/androgenic steroids and antiestrogens, as well as in Klinefelter’s syndrome. HAs are rarely found in children and are usually associated with metabolic disorders such as glycogen storage disease, diabetes mellitus, and Hurler’s disease.


Patients with HA often present with acute abdominal pain secondary to hemorrhage within the tumor. Intraperitoneal rupture produces hemoperitoneum and may lead to shock. Only one third of patients have an abdominal mass. Serum AFP levels are normal.




HEPATIC ADENOMA—FACT SHEET


Definition





  • Benign neoplasm of hepatocytes



Incidence and location





  • 3.4 per 100,000 in long-term users of oral contraceptives



  • Approximately 1.3 per million in women who have never used oral contraceptives



  • No geographic predilection



Morbidity and mortality





  • Hemorrhage in approximately 40% of patients



  • Mortality rate of 6% to 20% in patients with hemorrhage



Gender, race, and age distribution





  • More common in young to middle-aged women (average age 30 years)



  • Rare in men



  • In children, seen mainly in setting of glycogen storage disease types I and III, where they occur before age 20 (males to females, 2:1)



  • No race predilection



Clinical features





  • More than 90% of patients have history of OCP use for more than 5 years



  • Most common complaint is right upper quadrant abdominal pain



  • Occasionally seen in patients taking anabolic steroids



Radiologic features





  • Vascular lesion on CT scan, with irregular enhancement



  • MRI shows well-defined mass, low signal to slightly hyperintense on T1-weighted images



Prognosis and therapy





  • Surgical resection if technically possible



  • Withdrawal of estrogens may be indicated to reduce tumor size



  • Liver transplantation is considered for multiple lesions



  • Malignant transformation to HCC is rare




Radiologic features


HA is visualized as a vascular lesion on CT scan, with irregular enhancement. MRI shows a well-defined mass with low to slightly hyperintense signal on T1-weighted images.


Pathologic features


Gross findings


HA is a well-circumscribed, often subcapsular mass in the right lobe of an otherwise normal liver. Most are larger than 10 cm. Ruptured HAs may be obscured by blood clot and difficult to recognize, but the tumor is usually paler or more yellow than the adjacent liver ( Fig. 20-3 ). The cut surface has a variegated appearance, generally due to the presence of blood clot. Fibrous septa are usually a result of previous infarct.




FIGURE 20-3


Hepatic adenomas are sharply circumscribed lesions. Intrahepatic hemorrhage is common in resected specimens.


Microscopic findings


On first glance, most HAs resemble normal liver microscopically, being composed of virtually normal hepatocytes in cords that are one to two cells thick and separated by sinusoids lined by inconspicuous Kupffer cells. However, no normal portal tracts are present, and there is a notable lack of any biliary epithelium. The third key feature of HA is the presence of haphazardly distributed arteries and thin-walled veins ( Fig. 20-4 ). Hepatocellular rosettes (pseudoglands) should not be confused with bile ducts.




FIGURE 20-4


Hepatic adenoma. Normal portal structures are lacking, and there is no biliary epithelium. The hepatocytes are bland. Haphazardly arranged parenchymal vessels are characteristic.


The hepatocytes of HA frequently display clear or vacuolated cytoplasm due to accumulation of glycogen or fat. Cytoplasmic inclusions representing α 1 -antitrypsin, megamitochondria, and Mallory’s hyalin is occasionally found. Focal cellular pleomorphism and prominent nucleoli may occasionally be seen, especially in tumors associated with androgenic steroid use. Mitoses, vascular invasion, and stromal invasion are not seen in HA and are suggestive of malignancy. Various degenerative changes in HA include dilated sinusoids and larger blood-filled (pelioid) spaces, a myxoid stroma, and areas of necrosis, infarct, and hematoma.


A new classification of HAs has been proposed based on genotype-phenotype correlation. Based on two molecular criteria (presence of HNF1α or β-catenin mutation) and one histologic criterion (presence or absence of an inflammatory infiltrate), HAs can be subclassified into four categories: (1) HAs with mutations of the HNF1α gene, (2) HAs with β-catenin gene mutation, (3) tumors without β-catenin or HNF1α mutations with inflammatory features, and (4) lesions showing no mutation and no inflammatory component. Tumors in group 1 are the most common (30% to 50% of adenomas) and histologically show prominent steatosis without cellular atypia or inflammation. Type 2 tumors are more common in males, tend to show cytologic abnormalities and acinar growth pattern, and may show areas of either borderline lesion between HA and HCC or unequivocal HCC. Type 3 tumors are characterized by presence of inflammatory infiltrates (especially around portal tractlike structures) and telangiectatic areas ( Fig. 20-5 ). Most lesions previously classified as “telangectatic FNHs” are now classified as inflammatory/telangectatic adenoma, in that their molecular features and clinical behavior (propensity to bleed if not resected) mimic those of adenomas rather than FNHs. Finally, type 4 lesions comprise a minority of lesions and lack distinctive features.






FIGURE 20-5


A, Portal tractlike structures with chronic inflammatory infiltrate and dilated (telangectatic) sinusoids are characteristic of telangectatic adenomas. B, Portal tract like structures may contain poorly formed ductules ( arrow ) but lack normal, well-formed bile ducts.


The term adenomatosis is sometimes used for those cases with multiple (usually more than 10) adenomas. Because the etiologic associations appear to be similar for multiple and solitary adenomas, distinction between these two groups is probably not warranted on clinicopathologic grounds.




HEPATIC ADENOMA—PATHOLOGIC FEATURES


Gross findings





  • Yellow, tan, or red-brown solitary nodule in noncirrhotic liver



  • Most measure 5 to 15 cm



  • May be hemorrhagic



Microscopic findings





  • Benign hepatocytes without acinar architecture or portal tracts



  • Tumor cells often contain glycogen or fat



  • Thin-walled vascular channels scattered throughout tumor



  • No biliary epithelium



Fine-needle aspiration biopsy findings





  • Single population of benign hepatocytes



  • Absence of other cellular elements (bile duct epithelium, fibrous tissue)



Differential diagnosis





  • FNH



  • Well-differentiated HCC



  • Normal liver (needle biopsy)




Ancillary studies


Fine-needle aspiration biopsy


FNA biopsy shows a single population of benign hepatocytes and absence of other cellular elements such as bile duct epithelium and fibrous tissue.


Differential diagnosis


On biopsy, distinguishing HA from FNH, well-differentiated HCC, and normal liver may be difficult. Fibrous scars in HA are rare and lack the large vessels seen in the fibrous septa of FNH. As noted, HA lacks vascular invasion and significant mitotic activity, distinguishing it from well-differentiated HCC. The absence of an aberrant trabecular pattern in HA and the relatively low nuclear-to-cytoplasmic (N:C) ratio are also helpful features discriminating features. HA is distinguished from normal liver by the lack of normal portal tracts and the total absence of biliary epithelium.


Prognosis and therapy


Rupture with subsequent massive bleeding into the peritoneal cavity is the most common cause of death related to HA. Because of this risk, HAs are completely excised when technically possible. Liver transplantation is occasionally performed for very large or multiple lesions. There is a low, incompletely defined risk for transformation to HCC.


Macroregenerative and dysplastic (borderline) nodules


Numerous terms have been applied to large hepatocellular nodules arising in the setting of cirrhosis, but the following nomenclature is widely accepted. Macroregenerative nodules (MRNs) are larger than surrounding nodules but do not display other atypical features. Dysplastic or “borderline,” nodules (DNs) exhibit atypical architectural or cytologic features, but do not meet histologic criteria for HCC.




MACROREGENERATIVE NODULES AND DYSPLASTIC NODULES—FACT SHEET


Definition





  • MRN: large dominant nodule in cirrhotic liver



  • DN: putative precursor lesion to HCC; does not meet definite histologic criteria of malignancy



Incidence and location





  • Reflect the etiology of the underlying cirrhosis



Morbidity and mortality





  • Related to the risk for development of HCC



Gender, race, and age distribution





  • Reflects etiology of underlying cirrhosis



Clinical features





  • Arise in setting of cirrhosis



  • Asymptomatic



Radiologic features





  • Indistinguishable from cirrhotic nodules



Prognosis and therapy





  • Treatment of DNs is excision when possible, which also facilitates further pathologic classification



Prognosis depends on status of underlying cirrhosis





  • High risk for development of HCC




Pathologic features


Gross findings


Macroregenerative and dysplastic nodules are usually similar to other cirrhotic nodules, although they may be paler or more bile stained. A thick fibrous capsule or variegated appearance is more suggestive of small HCC. MRNs are larger than other cirrhotic nodules and may measure up to 5 cm or more in diameter ( Fig. 20-6 ). High-grade DNs resemble MRNs grossly but may appear less well circumscribed.




FIGURE 20-6


The macroregenerative nodule in this cirrhotic liver ( arrow ) is distinguishable from the background cirrhosis only by its larger size. The variegated nodule of similar size is a small hepatocellular carcinoma.


Microscopic findings


Most of the MRNs in cirrhosis are multiacinar, containing more than one portal tract scattered throughout the nodule. The hepatocytes within these nodules are identical to those in the surrounding liver. The hepatocellular plates are one or two cells thick. Prominent bile ductular reaction may be seen in the adjacent fibrous scar. The reticulin framework is intact, as in a typical cirrhotic nodule.


In DNs, the hepatocytes typically display nuclear density more than twice normal. Occasional foci of small cell change (small cell dysplasia; Fig. 20-7 A), characterized by smaller size and a greater N:C ratio than the surrounding hepatocytes, are seen. Other focal architectural and cytologic abnormalities include pseudoglands, large cell change (see Fig. 20-7 B), rare mitoses, and isolated liver plates that are three cells thick. Portal tracts may be structurally abnormal. Increased iron deposition is sometimes noted.




FIGURE 20-7


A, Dysplastic nodules often exhibit small cell change ( arrow ), a dysplastic change that is recognized by the presence of densely packed hepatocytes smaller than those of the surrounding liver. B, In large cell change, the hepatocytes are enlarged, with atypical, irregular nuclei and large nucleoli. Aberrant architecture of hepatocellular carcinoma is absent.




MACROREGENERATIVE NODULES AND DYSPLASTIC NODULES—PATHOLOGIC FEATURES


Gross findings





  • MRNs are larger than other nodules in cirrhotic liver; no difference in color or texture



  • DNs may be of any size; may be paler than other cirrhotic nodules and bile stained



Microscopic findings





  • MRNs are similar to other nodules in the cirrhotic liver



  • Low-grade DNs show minimal nuclear atypia and only slight architectural abnormalities; large cell change may be seen



  • High-grade DNs may show nodule-within-nodule architecture



  • Trabeculae are two cells thick; pseudoglands may be present



  • Increased mitotic activity



  • Focal liver cell atypia, with either small cell or large cell change



Fine-needle aspiration biopsy findings





  • Reactive hepatocytes in groups with irregular edges



  • Fibrous tissue



  • Abscess of endothelial cells wrapping around hepatocyte groups



  • Irregular distribution of dysplastic hepatocytes



Genetics





  • MRNs are polyclonal



  • Low- and high-grade DNs may be monoclonal or polyclonal



Differential diagnosis





  • Liver cell adenoma



  • HCC




Prognosis and therapy


DNs are considered an important precursor to HCC. Ablation or resection of the lesion is recommended because of the potential to develop into HCC. MRNs cannot always be reliably distinguished from low-grade DNs, and patients with apparent MRNs on imaging studies should be followed at frequent intervals.


Differential diagnosis


Separation of low-grade DNs from MRNs, as well as high-grade DNs from HCC, may be impossible on histologic grounds. Features more often seen in HCC are a moderate number of mitotic figures, hepatocyte plates more than three cells thick, marked reduction in the reticulin framework, and the absence of portal tracts. Vascular invasion is diagnostic of HCC, but it is rarely seen in these early lesions.


Hepatocellular carcinoma


Clinical features


Hepatocellular carcinoma is the single most common histologic type of epithelial primary liver tumor. Although relatively uncommon in Western countries, HCC is one of the most prevalent malignant tumors worldwide, responsible for 20% to 40% of cancer deaths in regions of high incidence, such as sub-Saharan Africa and Southeast Asia. In low-incidence areas, HCC is a tumor of elderly men. In areas of higher incidence, HCC occurs at earlier ages (20s to 30s) due to the high prevalence of perinatally acquired hepatitis B.


Virtually any chronic liver disease may predispose toward HCC. The most common predisposing condition is cirrhosis from any cause, with hepatitis B, hepatitis C, and alcoholic liver disease the most common causes. Obesity-related liver disease is increasingly recognized as a risk factor for HCC, and genetic hemochromatosis carries a particularly high risk. The annual risk for HCC developing in a cirrhotic liver is estimated at 1% to 6%.


Patients may present with abdominal pain, fullness or a mass, or clinical signs and symptoms of cirrhosis. HCC rarely presents with metastases. The most useful serum marker is elevation of AFP, which may be highly elevated in patients with large tumors. Of note, serum AFP levels may also be elevated viral hepatitis and cirrhosis. High AFP levels are also seen in hepatoid gastric adenocarcinomas and germ cell tumors containing a yolk sac component.




HEPATOCELLULAR CARCINOMA—FACT SHEET


Definition





  • Malignant neoplasm showing hepatocellular differentiation



Incidence and location





  • Most common primary liver malignancy in adults



  • In United States, incidence is 4 per 100,000



  • Wide geographic variation in incidence, with high incidence in Southeast Asia and sub-Saharan Africa, low incidence in Western countries



Morbidity and mortality





  • High mortality



  • Median survival for resectable tumors is up to 45 months; for unresectable tumors, less than 6 months



  • Patients with cirrhosis are at risk for development of new tumors



Gender, race, and age distribution





  • Male predominance 2:1 to 5:1



  • Predilection for Asian and African population probably due to chronic viral hepatitis and aflatoxin exposure



  • Incidence increases with age in Western countries (peak incidence seventh decade), but mean age in South Africa is 35 years



Clinical features





  • Associated with chronic hepatitis C and hepatitis B infections and exposure to aflatoxins



  • Commonly arises with a background of cirrhosis



  • Presentation is variable, ranging from decompensated liver disease to malaise, weight loss, and hepatomegaly



  • Serum AFP is elevated in approximately 50% of cases



Radiologic features





  • Ultrasonography is method of choice for screening in setting of cirrhosis



  • CT shows low-attenuation nodules



Prognosis and therapy





  • Prognosis is heavily dependent on status of liver disease



  • Treatment is surgical excision when feasible



  • Liver transplantation may be indicated when tumors are small and low stage



  • Palliative treatments include ethanol injection, cryoablation, and chemoembolization



  • Chemotherapy has limited benefit




Radiologic features


Advanced HCC is generally easily detected by ultrasonography, CT, or MRI. HCC on CT is usually low attenuation and may have daughter nodules. Ultrasonography is the most useful modality in screening for HCC in cirrhotic livers; a mosaic pattern with peripheral sonolucency is typical.


Pathologic features


Gross findings


Several macroscopic patterns of HCC are reported. HCC arising in a noncirrhotic liver usually grows as a single large mass, with or without satellite nodules, and may also exhibit this pattern in the setting of cirrhosis ( Fig. 20-8 A). However, tumors arising in cirrhosis often grow as numerous smaller nodules (diffuse type) that may be difficult to distinguish from the background liver (see Fig. 20-8 B). Tumor nodules are soft, bile stained, or yellow to tan; they often appear variegated due to foci of hemorrhage and necrosis (see Fig. 20-6 ). Separate tumor nodules may represent multicentric growth or may represent tumor spread via intrahepatic vascular routes. Macroscopic portal vein, hepatic vein, and bile duct invasion are present in some cases (see Fig. 20-8 C). Involvement of the inferior vena cava, sometimes with extension into the right atrium, may be found.




FIGURE 20-8


A, Variegated appearance and greenish color (due to the presence of bile) are characteristic of hepatocellular carcinoma (HCC). Satellite nodules are often present. B, In the cirrhotic liver, nodules of HCC may be difficult to distinguish from cirrhosis. C, Invasion of large veins is common.


Microscopic findings


Hepatocellular carcinoma typically displays obvious hepatocellular differentiation, with arrangement of cells resembling hepatocytes in a trabecular pattern outlined by sinusoids. Most HCCs have scant stroma. Bile production by neoplastic cells is pathognomonic of HCC but should not be confused with bile production by trapped non-neoplastic hepatocytes. The presence of bile canaliculi is also diagnostic. Cytoplasmic inclusions such as Mallory’s hyalin, α 1 -antitrypsin inclusions, and fat are frequently present, often in focal areas of the tumor or in individual tumor nodules. Vascular lakes may simulate peliosis hepatis. The World Health Organization classification divides tumors into well-, moderately, poorly, and undifferentiated grades. Although most tumors are moderately differentiated, more than one histologic grade is often present within a given tumor.


Four major histologic patterns are described and are frequently found together in the same tumor. Only the fibrolamellar type (FL-HCC) appears to have prognostic significance. The trabecular pattern consists of trabeculae that vary in thickness and are surrounded by sinusoids lined by flattened endothelial cells and Kupffer cells ( Fig. 20-9 A). In the compact or solid pattern, compression of broad trabeculae forms sheets with inconspicuous sinusoids (see Fig. 20-9 B). The pseudoglandular (acinar) variant, with dilated rounded spaces rounded by cytologically malignant hepatocytes, may be mistaken for adenocarcinoma (see Fig. 20-9 C). The lumen may contain bile. The rare scirrhous variant displays prominent desmoplastic stroma (see Fig. 20-9 D). Pleomorphic (giant cell), clear cell, and sarcomatoid variants are rare subtypes (see Figs. 20-9 E and F).














FIGURE 20-9


A, Trabecular architecture, with markedly thickened cell plates lined by endothelial cells, is the most common microscopic pattern in HCC. B, Pseudoglandular pattern may be prominent in HCC and may lead to an erroneous diagnosis of adenocarcinoma. Note the absence of a desmoplastic background. C, Solid (compact) pattern. D, Cytoplasmic clearing of neoplastic hepatocytes due to glycogen accumulation (clear cell pattern). E, Prominent bands of collagen are seen in the rare scirrhous pattern. Note that the cytologic features of fibrolamellar-hepatocellular carcinoma (FL-HCC) are not present. F, Pleomorphic pattern of HCC showing markedly enlarged, hyperchromatic nuclei, which were present throughout this lesion.




HEPATOCELLULAR CARCINOMA—PATHOLOGIC FEATURES


Gross findings





  • Single large mass, with or without satellite nodules, or multiple nodules diffusely involving the liver



  • Tumor is soft, often variegated, and bile stained



  • Vascular invasion is common, with involvement of portal or hepatic veins



Microscopic findings





  • Wide range of differentiation



  • Most tumors have trabecular growth pattern; pseudoglandular pattern is also common



  • Stroma is sparse in most tumors



  • Bile production, fat droplets, Mallory’s hyalin, and other cytoplasmic inclusions may be seen



Ultrastructural findings





  • Bile canaliculi may be demonstrated



Fine-needle aspiration biopsy findings





  • Highly cellular smears with cohesive nests and thick trabeculae of atypical hepatocytes



  • Cellular atypia may be minimal in well-differentiated tumors, with slight pleomorphism and increase in N:C ratio



  • Endothelial cells wrap around periphery of cell clusters



Genetics





  • TP53 mutations associated with progression from early to advanced stage



  • Frequent allelic losses on multiple chromosomes



Immunohistochemistry





  • Tumor cells are positive for HepPar-1 (hepatocyte), with a granular cytoplasmic pattern



  • Less than 50% of tumors are positive for AFP



  • Polyclonal CEA demonstrates a canalicular staining pattern; monoclonal CEA is negative



Differential diagnosis





  • HA



  • DN in cirrhosis



  • Metastatic tumors, especially neuroendocrine tumors



  • CC




Ancillary studies


Ultrastructural findings


Electron microscopy is rarely indicated, but demonstration of canaliculi or bile may be useful.


Fine-needle aspiration biopsy


Aspirates of HCC are generally highly cellular, and the tumor cells are polygonal with centrally placed hyperchromatic nuclei and variably prominent nucleoli. The N:C ratio is typically increased, varying with the degree of differentiation. Naked tumor cell nuclei are common and should not be confused with lymphoma. Intranuclear cytoplasmic invaginations and the various cytoplasmic deposits (bile, hyaline globules, Mallory’s hyalin), described in the section on histologic features, can be identified in cytologic preparations. Peripheral rimming of the tumor cell clusters by endothelial cells ( Fig. 20-10 ) is a helpful feature.




FIGURE 20-10


Hepatocellular carcinoma. Aspirates are hypercellular; large clusters of neoplastic hepatocytes rimmed by endothelial cells are common.


Immunohistochemistry


The most useful immunohistochemical markers for HCC are canalicular staining pattern with antibodies to CD-10 and certain antibodies to carcinoembryonic antigen (CEA), as well as positivity for hepatocyte (HepPar-1). Immunostaining with polyclonal anti-CEA antiserum or certain monoclonal CEA (m-CEA) antibodies that cross-react with canalicular biliary glycoprotein 1 demonstrates a canalicular pattern in up to 80% of HCCs ( Fig. 20-11 A). Positive staining with antisera to AFP is very suggestive of HCC (see Fig. 20-11 B). HepPar-1, a relatively hepatocyte-specific monoclonal antibody that reacts with a hepatocyte epitope that is resistant to formalin fixation and tissue processing, produces a granular cytoplasmic staining pattern in HCC and normal hepatocytes (see Fig. 20-11 C). Positive staining for α 1 -antitrypsin and alpha-1-antichymotrypsin is nonspecific.










FIGURE 20-11


A, A canalicular staining pattern with cross-reactive (polyclonal) antibodies to carcinoembryonic antigen (shown) and CD10 is characteristic of HCC. Note that both normal liver ( upper right ) and HCC ( lower left ) show the typical canalicular pattern. B, Immunohistochemistry for α-fetoprotein is patchy; only approximately 50% of HCC will stain for this marker. C, Hepatocyte antibody (HepPar-1) has a granular cytoplasmic staining pattern in HCC. Normal liver ( upper left ) shows similar pattern. D, Cytoplasmic and membranous pattern of glipican-3 reactivity in HCC. No staining is seen in normal liver ( right ).


Glypican-3 (an oncofetal protein) immunohistochemistry has also been shown to be a useful marker. Glypican-3 has a high sensitivity for poorly differentiated HCCs and can be used in this situation to differentiate the latter from cholangiocarcinomas and metastatic lesions (see Fig. 20-11 D). This marker is also expressed by most well-differentiated HCCs (although sensitivity may be lower than in poorly differentiated lesions). Positive staining is not seen in benign hepatocytic neoplasms.


Cytokeratin (CK) profiles are not particularly useful in diagnosis of HCC. In situ hybridization for albumin messenger RNA appears to be highly sensitive but is not widely used. In practice, many investigators currently use a panel of p-CEA or CD10 (canalicular pattern), m-CEA, HepPar-1, and AFP antibodies for diagnosis of HCC.


Differential diagnosis


Neuroendocrine tumors metastatic to the liver may be difficult to distinguish from HCC because of their trabecular architecture. However, the cells usually display the characteristic finely stippled chromatin pattern and lack prominent nucleoli. The presence of a delicate fibrovascular stroma surrounding groups of tumor cells favors neuroendocrine tumor, and diffuse positivity for neuroendocrine markers such as synaptophysin and chromogranin is helpful.


Hepatocellular carcinoma is distinguished from adenocarcinoma and cholangiocarcinoma (CC) by its trabecular growth pattern, lack of a fibrous stroma, and immunohistochemical profile, with canalicular staining pattern with p-CEA and CD10 and cytoplasmic positivity for HepPar-1 and AFP.


Prognosis and therapy


Hepatocellular carcinoma generally carries a very poor prognosis, with survival after diagnosis measured in months. The prognosis is determined primarily by HCC stage and the functional status of the liver. Nonoperative palliative therapies include percutaneous ethanol injection, cryoablation, and transcatheter arterial chemoembolization; chemotherapy has largely proven ineffective. At autopsy, metastases, most commonly to lung and porta hepatis lymph nodes, are found in up to 75% of patients. Bone, adrenal gland, and virtually any site in the body can be involved by metastatic disease. Tumor size, number and location (one or both lobes) of tumor nodules, presence of gross or microscopic vascular invasion, and disease status of the uninvolved liver are the most important prognostic variables. In carefully selected patients, hepatic resection and/or liver transplantation may be performed with success. Small, low-stage, incidentally discovered HCCs in a cirrhotic liver at transplantation do not adversely affect outcome.


Fibrolamellar carcinoma


Clinical features


Fibrolamellar-hepatocellular carcinoma (FL-HCC) is a rare HCC variant arising in noncirrhotic liver in young patients. It is associated with a better prognosis than typical HCC, perhaps because of the younger age of the patients and their lack of significant underlying liver disease. Clinical presentation is similar to typical HCC. In most cases serum AFP levels are normal or only modestly elevated.




FIBROLAMELLAR CARCINOMA—FACT SHEET


Definition





  • Rare variant of HCC with characteristic pathologic findings and distinctive clinical features



Incidence and location





  • Rare in Asian and African countries



  • Age-adjusted incidence rate approximately 0.02 per 100,000



Morbidity and mortality





  • More indolent course than typical HCC



Gender, race, and age distribution





  • Male to female ratio 3:4



  • No race predilection in U.S. population



  • Mean age 23 years



Clinical features





  • Symptoms are nonspecific: nausea, weight loss, abdominal pain, malaise



  • Not associated with chronic viral hepatitis or cirrhosis



  • Normal serum AFP



Radiologic features





  • Well-demarcated hypodense tumor on CT scan



  • Central scar may mimic FNH



Prognosis and therapy





  • Approximately 60% are surgically resectable



  • Chemotherapy is reserved for patients with unresectable disease and is not curative



  • Liver transplantation may be considered if tumor is confined to the liver



  • Most significant determinant of survival is tumor stage



  • 5-year survival rate is approximately 60%




Pathologic features


Gross findings


Most FL-HCCs arise in the left lobe, but large tumors may affect both lobes. The tumors are usually solitary, firm, and well circumscribed and may be bile stained, necrotic, or hemorrhagic. They are typically large, measuring up to 25 cm. A central stellate scar similar to that seen in FNH may be present ( Fig. 20-12 ). The adjacent non-neoplastic liver is unremarkable.




FIGURE 20-12


Fibrolamellar carcinoma (FL-HCC) is usually a single mass; note the noncirrhotic adjacent liver and the central stellate scar.


Microscopic findings


The tumor cells of FL-HCC are very large, display abundant granular eosinophilic cytoplasm (due to large numbers of mitochondria) and distinct cell borders, and have a distinctive oncocytic appearance ( Fig. 20-13 A). A defining feature of FL-HCC is the presence of parallel bands of hyalinized fibrous tissue separating the tumor cells into nests (see Fig. 20-13 B). Cytoplasmic eosinophilic hyaline globules, which may be periodic acid-Schiff (PAS) positive diastase resistant, may represent α 1 -antitrypsin. Cytoplasmic pale bodies contain fibrinogen and are present in about 50% of cases.




FIGURE 20-13


A, The cells of FL-HCC are very large and polygonal, with abundant granular pink cytoplasm (oncocytes). Central nucleus with prominent nucleolus is also characteristic. B, Dense collagen bundles are arranged in parallel layers.




FIBROLAMELLAR CARCINOMA—PATHOLOGIC FEATURES


Gross findings





  • Two thirds are located in left lobe



  • Single mass in 56% of cases



  • Firm tan or green circumscribed mass



  • Central scar in many cases



  • Surrounding liver is noncirrhotic



Microscopic findings





  • Lamellar fibrous stroma



  • Large polygonal, granular oncocytic tumor cells



  • Cytoplasmic inclusions contain pale bodies (accumulated fibrinogen), Mallory’s hyalin, α 1 -antitrypsin



Ultrastructural findings





  • Numerous densely packed mitochondria



Fine needle aspiration biopsy findings





  • Aspirate often paucicellular



  • Discohesive large hepatocytes with granular cytoplasm



  • Intranuclear pseudoinclusions and macronucleoli



Genetics





  • 4q+, 9p−, 16p−, and Xq− have been reported



Immunohistochemistry





  • Positive for HepPar-1 (hepatocyte)



  • Polyclonal CEA positive with a canalicular distribution



  • AFP negative



Differential diagnosis





  • FNH



  • Ordinary HCC



  • CC




Ancillary studies


Ultrastructural findings


The cytoplasm contains numerous mitochondria, as expected from the oncocytic appearance of the tumor cells. Dense core neuroendocrine-like granules may also be found.


Differential diagnosis


The most common lesions in the differential diagnosis for FL-HCC are FNH, typical HCC, and metastatic tumors with extensive fibrosis. Although FNH and FL-HCC may have central stellate scars, microscopically the lack of hepatocellular atypia distinguishes FNH from FL-HCC. The presence of grossly detectable bile staining and a diameter greater than 5 cm strongly suggest FL-HCC. Diffuse lamellar fibrosis combined with oncocytic cellular features is not found in typical HCC. In metastatic carcinomas, the collagen is more haphazardly arranged and lacks the lamellar features characteristic of FL-HCC. The tumor cells in scirrhous HCC are smaller, do not display oncocytic features, and form glandular patterns.


Prognosis and therapy


FL-HCC is often resectable and thus associated with a better outcome than usual HCC. Hepatic transplantation may be considered for nonresectable tumors confined to the liver. The most common metastatic sites are abdominal lymph nodes, peritoneum, and lung.


Hepatoblastoma


Clinical features


Hepatoblastoma (HB) is the most common primary hepatic tumor in children, accounting for about 50% of all primary pediatric hepatic malignancies; the majority occurs by 2 years of age. There is a male predominance (2:1). Patients generally present with an abdominal mass noticed by the parent, but some patients present with precocious puberty related to human chorionic gonadotropin production by the tumor. Roughly 5% of patients have an associated congenital abnormality. Familial adenomatous polyposis is associated with higher risk for HB. Although the etiologic factors of HB are unknown, an association with low birth weight is recognized, although it is not clear if an environmental cause is responsible. The serum AFP level is elevated in 90% of cases.




HEPATOBLASTOMA—FACT SHEET


Definition





  • Malignant liver tumor occurring in children, mimicking fetal or embryonal liver and often containing heterologous cell types



Incidence and location





  • Rare; annual incidence in United States is 0.2 per 100,000 children



  • 47% of pediatric malignant liver tumors



Morbidity and mortality





  • Overall survival is 65% to 70%



Gender, race, and age distribution





  • Male predominance 2:1



  • No racial predilection



  • 90% occur within first 5 years of life



Clinical features





  • More common in low-birth-weight infants



  • Presenting symptom is enlarging abdomen noted by parent



  • Weight loss and anorexia are less common



  • 5% of children with HB have congenital anomalies



  • Human chorionic gonadotropin production may lead to presentation with precocious puberty



Radiologic features





  • Solid or multifocal mass on CT



  • Calcification in greater than 50% of cases



  • MRI shows decreased signal relative to normal liver on T1-weighted images, increased signal on T2-weighted images



Prognosis and therapy





  • Tumor stage is key prognostic factor



  • Pure fetal type may have a better prognosis; small cell undifferentiated pattern has a worse prognosis



  • Treatment is surgical excision when possible



  • Preoperative chemotherapy allows many previously unresectable cases to be completely resected




Radiologic features


HB is visualized as a solid or multifocal mass on CT, with calcification in more than half of cases. MRI shows decreased signal relative to the normal liver on T1-weighted images and increased signal on T2-weighted images.


Pathologic features


Gross findings


HB is typically a solitary mass most often located in the right lobe. Tumors may be quite large, measuring up to 20 cm. Purely epithelial HB is a soft, fleshy, tan-white mass ( Fig. 20-14 ); those with a prominent mesenchymal component are often firm and may be calcified. Cystic degeneration, necrosis, and hemorrhage may be seen.




FIGURE 20-14


Hepatoblastoma (HB) is a single large mass; epithelial tumors are soft and fleshy.


Microscopic findings


HBs may be classified as either epithelial or mixed epithelial-mesenchymal and are subclassified into six patterns.



  • 1.

    Fetal pattern (30%). In this pattern the hepatocytes are uniform and similar to normal hepatocytes, although they have a slightly higher N:C ratio. An alternating light and dark pattern is characteristic on low power ( Fig. 20-15 A). Mitoses are typically rare (less than 2 per 10 high-power fields). The tumor cells form cords two to three cells thick, separated by sinusoids, in a pattern reminiscent of normal liver. However, normal structures such as portal tracts, bile ducts, and bile ductules are absent.




    FIGURE 20-15


    A, The fetal pattern of HB exhibits alternating areas of light- and dark-staining tumor cells showing hepatocellular differentiation. B, Osteoid is the most common mesenchymal element and may be abundant following chemotherapy.


  • 2.

    Embryonal pattern (20%). The tumor cells in the embryonal pattern are less differentiated and cohesive compared with those of the fetal pattern and have a higher N:C ratio and coarser chromatin. The trabecular pattern is not well developed, and the tumor cells may form sheets. Mitoses and necrosis are more common than in the fetal pattern.


  • 3.

    Macrotrabecular pattern (3%). This pattern is characterized by broad trabeculae 10 or more cells thick. Trabeculae may be composed of embryonal or fetal cells.


  • 4.

    Small cell undifferentiated pattern (3%). This pattern is the least differentiated pattern and resembles other small blue cell tumors of childhood. The tumor is composed of loosely cohesive sheets of uniform small cells with scanty cytoplasm. The tumor cells are positive for CK.


  • 5.

    Mixed epithelial and mesenchymal pattern (44%). This pattern is characterized by areas of both epithelial and mesenchymal differentiation. The primitive mesenchymal component may be primitive, with spindle or stellate cells with little cytoplasm, or display differentiation along chondroid and rhabdomyoblastic lines. Osteoid is the most frequent heterologous element and may be more prominent after chemotherapy (see Fig. 20-15 B). The mesenchymal elements may be CK positive, suggesting sarcomatoid metaplasia of the epithelial component.


  • 6.

    A subtype of mixed pattern tumors displays teratoid features and may contain elements of mature teratoma such as keratinized squamous epithelium, intestinal epithelium, and neuroectodermal structures.





HEPATOBLASTOMA—PATHOLOGIC FEATURES


Gross findings





  • Single well-circumscribed mass in 80% of cases



  • Pure fetal tumors are soft, tan to brown, and coarsely lobulated



  • Mixed epithelial and mesenchymal tumors have a variegated, heterogeneous cut surface



Microscopic findings





  • Six histologic subtypes



  • Pure fetal epithelial pattern (approximately 30%) is composed of sheets of uniform cells resembling fetal hepatocytes



  • Embryonal pattern consists of a mixture of fetal-type cells and smaller less differentiated cells with higher N:C ratio



  • Macrotrabecular pattern: epithelial HB with trabeculae more than 10 cells thick



  • Small cell undifferentiated pattern is composed of discohesive sheets of small cells indistinguishable from other small blue cell tumors of childhood



  • Mixed epithelial and mesenchymal pattern contains fetal and embryonal epithelial cells and primitive mesenchyme with various mesenchymal tissues such as fibrous tissue, osteoid, and cartilage



  • Teratoid pattern contains a variety of tissue types in addition to those found in the mixed pattern, such as skeletal muscle, bone, or squamous epithelium



Ultrastructural findings





  • Small cell tumors have relatively dense cytoplasm with tonofilaments, intercellular junctions, and microvilli



  • Glycogen accumulation and bile canaliculi may be seen in epithelial components



Fine-needle aspiration biopsy findings





  • Very cellular smears



  • Cohesive nests and sheets of small, crowded, atypical hepatocytes



  • High N:C ratio and vacuolated or granular cytoplasm



  • May contain spindle cell or mesenchymal component



  • Small cell type is indistinguishable from other small round blue cell tumors on smear



Genetics





  • Associated with familial adenomatous polyposis (APC gene mutations)



  • Trisomy 2, trisomy 20, 4q structural rearrangements are the most common chromosomal abnormalities



  • Stabilizing mutations in β-catenin activate Wnt pathway



Immunohistochemistry





  • Epithelial components are hepatocyte positive, AFP positive, epithelial membrane antigen positive



  • Small cell pattern is CK positive



  • Mesenchymal areas are vimentin positive



Differential diagnosis





  • HCC



  • Other small blue cell tumors of childhood




Ancillary studies


Fine-needle aspiration biopsy


FNA biopsy yields highly cellular smears with cohesive nests and sheets of small atypical hepatocytes. The aspirate may contain a spindle cell or mesenchymal component.


Differential diagnosis


HB with a predominantly or exclusively small cell component may be difficult to distinguish from the small, round cell tumors such as neuroblastoma, lymphoma, and rhabdomyosarcoma. The presence of more differentiated areas of HB and the tumor cell immunophenotype (CK positive; leukocyte common antigen, neurofilament, and desmin negative) distinguish small cell HB from other neoplasms. The absence of a renal mass generally excludes Wilms’ tumor. The macrotrabecular variant of HB closely resembles HCC; however, HCC is exceedingly rare in the age group affected by HB.


Other considerations include sarcomas, such as undifferentiated (embryonal) sarcoma, which are excluded by the lack of an epithelial component. Germ cell tumor must be considered in the differential diagnosis but is generally excluded by the focal nature of the teratoid areas in HB.


Prognosis and therapy


Outcome is dependent on tumor resectability. Most patients are treated with neoadjuvant multiagent chemotherapy, and currently the rate of resection is over 90%. More than 70% of patients have long-term survival. The most frequent metastatic sites are regional lymph nodes and lung. Liver transplantation may be considered in some cases in which tumor is limited to the liver but is unresectable.


Histologic pattern is generally not an independent predictor of prognosis, although the small cell undifferentiated pattern does appear to correlate with a poorer prognosis, and completely resected pure fetal tumors may have a more favorable outcome. Other unfavorable prognostic features are increased mitotic activity, vascular invasion, incomplete tumor resection, and AFP levels of less than 100 ng/mL at diagnosis.


Biliary tumors


Bile duct hamartoma


Clinical features


Bile duct hamartomas (BDHs), also known as von Meyenburg complexes, are small, incidental, clinically asymptomatic lesions, reported in up to 27% of all autopsies. BDH is considered part of the spectrum of ductal plate malformation and may be related to autosomal dominant polycystic kidney disease, congenital hepatic fibrosis, or other genetic disorders, as well as being found on a sporadic basis.



Mar 12, 2019 | Posted by in GASTROENTEROLOGY | Comments Off on Liver neoplasms

Full access? Get Clinical Tree

Get Clinical Tree app for offline access